Logo image of INAB

IN8BIO INC (INAB) Stock Fundamental Analysis

USA - NASDAQ:INAB - US45674E2081 - Common Stock

2.35 USD
-0.04 (-1.67%)
Last: 10/6/2025, 7:01:59 PM
Fundamental Rating

1

Overall INAB gets a fundamental rating of 1 out of 10. We evaluated INAB against 536 industry peers in the Biotechnology industry. INAB has a bad profitability rating. Also its financial health evaluation is rather negative. INAB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INAB has reported negative net income.
INAB had a negative operating cash flow in the past year.
INAB had negative earnings in each of the past 5 years.
INAB had a negative operating cash flow in each of the past 5 years.
INAB Yearly Net Income VS EBIT VS OCF VS FCFINAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -123.33%, INAB is not doing good in the industry: 80.60% of the companies in the same industry are doing better.
INAB has a Return On Equity of -156.77%. This is in the lower half of the industry: INAB underperforms 63.43% of its industry peers.
Industry RankSector Rank
ROA -123.33%
ROE -156.77%
ROIC N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
INAB Yearly ROA, ROE, ROICINAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

INAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INAB Yearly Profit, Operating, Gross MarginsINAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

INAB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for INAB has been increased compared to 5 years ago.
Compared to 1 year ago, INAB has a worse debt to assets ratio.
INAB Yearly Shares OutstandingINAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
INAB Yearly Total Debt VS Total AssetsINAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -11.33, we must say that INAB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.33, INAB is doing worse than 75.75% of the companies in the same industry.
INAB has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, INAB is in line with its industry, outperforming 44.40% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -11.33
ROIC/WACCN/A
WACCN/A
INAB Yearly LT Debt VS Equity VS FCFINAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 7.03 indicates that INAB has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.03, INAB is doing good in the industry, outperforming 69.22% of the companies in the same industry.
INAB has a Quick Ratio of 7.03. This indicates that INAB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INAB (7.03) is better than 69.78% of its industry peers.
Industry RankSector Rank
Current Ratio 7.03
Quick Ratio 7.03
INAB Yearly Current Assets VS Current LiabilitesINAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

INAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.69%, which is quite impressive.
EPS 1Y (TTM)63.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, INAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.09% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.34%
EPS Next 2Y35.26%
EPS Next 3Y21.94%
EPS Next 5Y19.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INAB Yearly Revenue VS EstimatesINAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 50M 100M 150M
INAB Yearly EPS VS EstimatesINAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INAB Price Earnings VS Forward Price EarningsINAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INAB Per share dataINAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as INAB's earnings are expected to grow with 21.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.26%
EPS Next 3Y21.94%

More info and screens

0

5. Dividend

5.1 Amount

INAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IN8BIO INC

NASDAQ:INAB (10/6/2025, 7:01:59 PM)

2.35

-0.04 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners16.77%
Inst Owner Change0%
Ins Owners3.26%
Ins Owner Change0%
Market Cap10.67M
Analysts82
Price Target64.52 (2645.53%)
Short Float %1.57%
Short Ratio0.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.76%
Min EPS beat(2)-2.94%
Max EPS beat(2)32.46%
EPS beat(4)3
Avg EPS beat(4)21.33%
Min EPS beat(4)-2.94%
Max EPS beat(4)47.71%
EPS beat(8)4
Avg EPS beat(8)4.71%
EPS beat(12)6
Avg EPS beat(12)1.63%
EPS beat(16)9
Avg EPS beat(16)1.64%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-49.5%
PT rev (3m)-41.27%
EPS NQ rev (1m)23.12%
EPS NQ rev (3m)23.12%
EPS NY rev (1m)19.4%
EPS NY rev (3m)14.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)-9.04
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-3.79
FCFYN/A
OCF(TTM)-3.79
OCFYN/A
SpS0
BVpS3.36
TBVpS3.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -123.33%
ROE -156.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.03
Quick Ratio 7.03
Altman-Z -11.33
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)217.04%
Cap/Depr(5y)140.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.25%
EPS Next Y68.34%
EPS Next 2Y35.26%
EPS Next 3Y21.94%
EPS Next 5Y19.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.28%
EBIT Next 3Y-17.46%
EBIT Next 5Y-5.55%
FCF growth 1Y42.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.07%
OCF growth 3YN/A
OCF growth 5YN/A